Latest Evidence on Sulfonylureas: What’s New?

por Leiter, Lawrence A.
Publicado 2020

Ongoing Clinical Trials of the Pleiotropic Effects of Statins

por Davignon, Jean, Leiter, Lawrence A
Publicado 2005

Should C-Reactive Protein Be a Target of Therapy?

por Oh, Jisun, Teoh, Hwee, Leiter, Lawrence A.
Publicado 2011

Should A1C Targets Be Individualized for All People With Diabetes?: Arguments for and against

por Teoh, Hwee, Home, Philip, Leiter, Lawrence A.
Publicado 2011

Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial

por Leiter, Lawrence A., Shestakova, Marina V., Satman, Ilhan
Publicado 2018

The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus

por Pitt, Bertram, Steg, Gabriel, Leiter, Lawrence A., Bhatt, Deepak L.
Publicado 2021

Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin

por Leiter, Lawrence A., Langslet, Gisle, Vijapurkar, Ujjwala, Davies, Michael J., Canovatchel, William
Publicado 2016

Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data

por Davidson, Jaime A., Stager, William, Paranjape, Sachin, Berria, Rachele, Leiter, Lawrence A.
Publicado 2020

Gaps and barriers in the control of blood glucose in people with type 2 diabetes

por Blonde, Lawrence, Aschner, Pablo, Bailey, Clifford, Ji, Linong, Leiter, Lawrence A, Matthaei, Stephan
Publicado 2017

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada

por Lachaine, Jean, Charron, Jean-Nicolas, Gregoire, Jean C, Hegele, Robert A, Leiter, Lawrence A
Publicado 2023

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada

por Johansen, Pierre, Håkan-Bloch, Jonas, Liu, Aiden R., Bech, Peter G., Persson, Sofie, Leiter, Lawrence A.
Publicado 2019

Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes

por Arnold, Suzanne V., Gosch, Kensey, Wong, Nathan D., Hejjaji, Vittal, Goyal, Abhinav, Leiter, Lawrence A., Kosiborod, Mikhail
Publicado 2020

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled...

por Cefalu, William T., Leiter, Lawrence A., de Bruin, Tjerk W.A., Gause-Nilsson, Ingrid, Sugg, Jennifer, Parikh, Shamik J.
Publicado 2015

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 OD...

por Bays, Harold E., Leiter, Lawrence A., Colhoun, Helen M., Thompson, Desmond, Bessac, Laurence, Pordy, Robert, Toth, Peter P.
Publicado 2017

From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes

por Mosenzon, Ofri, Del Prato, Stefano, Schechter, Meir, Leiter, Lawrence A., Ceriello, Antonio, DeFronzo, Ralph A., Raz, Itamar
Publicado 2021

Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?

por Bays, Harold, Conard, Scott, Leiter, Lawrence A, Bird, Steven, Jensen, Erin, Hanson, Mary E, Shah, Arvind, Tershakovec, Andrew M
Publicado 2010

Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub‐analysis of ODYSSEY COMBO II

por Leiter, Lawrence A., Zamorano, José Luis, Bujas‐Bobanovic, Maja, Louie, Michael J., Lecorps, Guillaume, Cannon, Christopher P., Handelsman, Yehuda
Publicado 2017

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment

por Hanefeld, Markolf, Arteaga, Juan M., Leiter, Lawrence A., Marchesini, Giulio, Nikonova, Elena, Shestakova, Marina, Stager, William, Gómez‐Huelgas, Ricardo
Publicado 2017

Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials

por Ganda, Om P., Plutzky, Jorge, Sanganalmath, Santosh K., Bujas‐Bobanovic, Maja, Koren, Andrew, Mandel, Jonas, Letierce, Alexia, Leiter, Lawrence A.
Publicado 2018

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

por Leiter, Lawrence A., Bain, Stephen C., Hramiak, Irene, Jódar, Esteban, Madsbad, Sten, Gondolf, Theis, Hansen, Thomas, Holst, Ingrid, Lingvay, Ildiko
Publicado 2019